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Abstract
Background: The aim of our study was to evaluate the prognostic value of MR-proADM and PCT levels in febrile
patients in the ED in comparison with a disease severity index score, the APACHE II score. We also evaluated the
ability of MR-proADM and PCT to predict hospitalization.
Methods: This was an observational, multicentric study. We enrolled 128 patients referred to the ED with high fever
and a suspicion of severe infection such as sepsis, lower respiratory tract infections, urinary tract infections,
gastrointestinal infections, soft tissue infections, central nervous system infections, or osteomyelitis. The APACHE II
score was calculated for each patient.
Results: MR-proADM median values in controls were 0.5 nmol/l as compared with 0.85 nmol/l in patients
(P< 0.0001), while PCT values in controls were 0.06 ng/ml versus 0.56 ng/ml in patients (P < 0.0001). In all patients
there was a statistically significant stepwise increase in MR-proADM levels in accordance with PCT values
(P < 0.0001). MR-proADM and PCT levels were significantly increased in accordance with the Apache II quartiles
(P < 0.0001 and P = 0.0012 respectively).
In the respiratory infections, urinary infections, and sepsis-septic shock groups we found a correlation between the
Apache II and MR-proADM respectively and MR-proADM and PCT respectively. We evaluated the ability of MR-
proADM and PCT to predict hospitalization in patients admitted to our emergency departments complaining of
fever. MR-proADM alone had an AUC of 0.694, while PCT alone had an AUC of 0.763. The combined use of PCT and
MR-proADM instead showed an AUC of 0.79.
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Conclusions: The present study highlights the way in which MR-proADM and PCT may be helpful to the febrile
patient’s care in the ED. Our data support the prognostic role of MR-proADM and PCT in that setting, as
demonstrated by the correlation with the APACHE II score. The combined use of the two biomarkers can predict a
subsequent hospitalization of febrile patients. The rational use of these two molecules could lead to several
advantages, such as faster diagnosis, more accurate risk stratification, and optimization of the treatment, with
consequent benefit to the patient and considerably reduced costs.
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Background
Fever is a common symptom in the Emergency
Department (ED), and it is highly suggestive of microbial
infection [1]. Accurate identification of fever aetiology in
patients presenting to the ED is a desirable objective,
but often it is unattainable, largely because signs and
symptoms of bacterial and viral infections considerably
overlap each other and often are nonspecific. This leads
to a delay in establishing a fast aetiological diagnosis in
the ED and to an inappropriate use of antibiotics [2].
Usually, the estimation of the bacterial infections’ sever-
ity is primarily based on the presence of some character-
istics suggestive of Systemic Inflammatory Response
Syndrome (SIRS) as defined by the American College of
Chest Physicians/Society of Critical Care Medicine
Consnensus Conference, 1992[3]. This, however, may
not be apparent when the patient is seen in the very
first hours of the illness.
Also, this syndrome is not specific enough to distin-
guish infectious from non-infectious causes of inflamma-
tion, because by definition SIRS parameters can be
altered in any inflammatory condition. Distinguishing
between various causes of fever is based upon a combin-
ation of clinical parameters as well as laboratory values,
including C-reactive protein (CRP) and leukocyte count
[4]. In addition to these, Procalcitonin (PCT) has been
suggested to be a novel infection biomarker [5]. Medical
literature has demonstrated that in critically ill patients
with sepsis, PCT is superior to CRP in diagnosing bac-
terial infections [6,7]. Another molecule studied in fe-
brile and septic patients is Adrenomedullin (ADM), a 52
amino acids peptide with immune modulating, meta-
bolic, and vasodilator activity. Its widespread production
in the tissues helps to maintain a blood supply in every
organ. Moreover ADM has a bactericidal activity and
could be helpful in the evaluation of sepsis’ diagnosis
and prognosis and in monitoring such conditions [8].
The Mid Regional fragment of pro–Adrenomedullin
(MR-proADM), included between amino acids 45-92, is
the more stable part of the ADM, and it has been
detected in plasma of patients with septic shock as a
consequence of the ADM active peptide degradation [9].
Febrile critically ill patients are a challenge for the
emergency physician. It is crucial to make an accurate
diagnosis as soon as possible and to risk stratify these
patients in order to start prompt and appropriate treat-
ment and to define their disposition.
Currently, no data are available on the combined use
of PCT and MR-proADM in risk stratification of febrile
patients admitted to the ED [10]. Few data are available
on the use of PCT only in the ED [11].
The aim of our study was to evaluate the prognostic
value of MR-proADM and PCT levels in a cohort of
well-defined febrile patients in the ED in comparison
with a disease severity index score, the Acute Physiology
And Chronic Health Evaluation (APACHE II) score. This
is a prognostic score used to predict mortality of critic-
ally ill patients, obtained by combining several para-
meters detected during the first hours after the
admittance in a critical care setting. When used together
with an accurate description of disease, it can prognos-
tically stratify acutely ill patients [12].
We also evaluated the ability of MR-proADM and
PCT to predict hospitalization of patients who arrive at
the ED with fever.
Methods
We enrolled 128 consecutive febrile critically ill patients
admitted to the ED of three teaching hospitals in Rome,
Italy (Sant’Andrea Hospital, Agostino Gemelli Hospital,
and Tor Vergata Hospital). The study was approved by
Sant’Andrea Hospital Ethics Committee, Agostino
Gemelli Hospital Ethics Committee, and Tor Vergata
Hospital Ethics Committee. All patients provided written
informed consent. This was an observational, multi-
centric study with an enrollment period of 12 months
(from October 2009 to October 2010). Patients referred
to the ED with fever (body temperature > 37 °C) and a
suspicion of severe infection such as sepsis, lower re-
spiratory tract infections, urinary tract infections, gastro-
intestinal (GI) infections, soft tissue infections, central
nervous system (CNS) infections, or osteomyelitis were
sequentially recruited. Patients younger than 18 years
old were excluded. After admittance to the emergency
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room, each patient was clinically examined by the emer-
gency physician. Blood sampling and radiological exams
were performed in accordance with guidelines [13]. For
each patient a blood sample for PCT and MR-proADM
was collected. The physician was blinded about the
results of both the biomarkers before starting any treat-
ment. Blood was obtained from peripheral venous cathe-
ters. The blood was separated into plasma immediately
after sampling, and aliquots of these samples were stored
at -80 °C and then analyzed.
MR-proADM and PCT were measured in 50 ul of
plasma by a Time-Resolved Amplified Cryptate Emission
(TRACE) technology assay, using kits designed for auto-
mated sandwich immunofluorescent assay of MR-proADM
and PCT, respectively (KRYPTOR; BRAHMS AG). The
KRYPTOR MR-proADM and PCT assays have a detec-
tion range of 0.05–100 nmol/L and 0.02-5000 ng/mL,
respectively.
For each patient the emergency physician calculated
the APACHE II score and completed a standardized case
report form, including history, co-morbidity, vital signs,
physical examination, and putative source of infections.
The form ended with the emergency physician’s diagnos-
tic suspicion, any antibiotic prescription, and the
patient’s course.
A control group was considered for the comparison of
PCT and MR-ProADM values between patients and the
control group itself, assuming that high values of both
molecules could be useful in diagnosing an infectious
source in the febrile patients admitted to the ED. The
control group was made up of 40 healthy volunteers,
older than 18 years, who had no past medical history
and were not on medication.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation (SD) or median with interquartile range (IQR)
in parenthesis, unless stated otherwise. Statistical
analysis was performed using Graph Pad Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA), SPSS
V.18 (© Copyright IBM Corporation) and SigmaPlot
V.1 1 (Copyright © 2008 Systat Software, Inc.).
Two-group non-parametric comparisons were calcu-
lated by the Mann–Whitney U test. For multigroup
comparisons, the Kruskal–Wallis test was used. Correl-
ation analyses were performed using Spearman rank
correlation. All statistical tests were two-tailed, and
P < 0.05 was considered statistically significant.
The APACHE II score was calculated with data obtained
at admittance and was expressed as percentage of pre-
dicted mortality (Predicted Death Rate = eLogit/(1 + eLogit);
Logit = -3,517+ (APACHE II) * 0,146) [12].
To determine the ability of the two biomarkers to pre-
dict hospitalization, a receiver operating characteristic
(ROC) curve was calculated.
Results
Patients’ characteristics are shown in Table 1.
MR-proADM and PCT
MR-proADM and PCT values were compared between
healthy subjects (control group) and patients (Figure 1a, b).
MR-proADM median (range) values in controls were
0.5 nmol/l (0.40–0.58 nmol/l) as compared with
0.85 nmol/l (0.50–1.68 nmol/l) in patients (P< 0.0001),
while PCT values in controls were 0.06 ng/ml (0.04–
0.08 ng/ml) versus 0.56 ng/ml (0.1–3.4 ng/ml) in
patients (P < 0.0001) (Table 1b).
MR-proADM levels showed a correlation with PCT
levels in the patients’ group (r = 0.57, P < 0.0001). In all
patients there was a statistically significant stepwise
increase in MR-proADM levels in accordance with
PCT values (P< 0.0001 - Figure 2).
According to the final diagnosis made in the ED, the
patients were divided into five different groups. The
principal diagnosis and relative groups are summarized
in Table 2.
Table 1 Patient’s characteristics
A
ALL PATIENTS CONTROL
GENDER 68 MALE – 60 FEMALE 23 MALE – 17 FEMALE
MEAN ± SD MEDIAN (IQR) RANGE (MIN-MAX) MEAN ± SD MEDIAN (IQR) RANGE (MIN-MAX)
AGE (Y) 61 ± 19 65 (45-77) 18-96 55 ± 15 58.5 (45-70) 29-76
TEMPERATURE (°C) 38.7 ± 0.7 38.6 (38.1-39) 37-41 36.4 ± 0.3 36.4 (36.1-36.5) 36-36,7
B
PCT (ng/ml) 3.85 ± 7.63 0.56* (0.10-3.44) 0.02-41.06 0.06 ± 0.02 0.06* (0.04-0.08) 0.02-0.11
MR-ProADM (nmol/ml) 1.72 ± 0.10 0.85** (0.50-1.68) 0.05-15.3 0.50 ± 0.10 0.50** (0.40-0.58) 0.31-0.65
APACHE II (%) 13.5 ± 11.21 9.9 (6.70-15.50) 2.9-76
*p < 0.0001.
**p < 0.0001.
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APACHE II score analysis
The APACHE II score, expressed in predicted mortality
percentage, was grouped into quartiles and compared re-
spectively with MR-proADM and PCT levels. MR-
proADM and PCT levels were significantly stepwise
increased in accordance with the APACHE II quartiles
(P<0.0001 and P=0.0012 respectively) (Figure 3a and b).
Furthermore, the correlation between MR-proADM
and PCT in each APACHE II quartile group was tested.
A positive correlation was shown in quartile 2 (r = 0.64,
P=0.0005), quartile 3, (r = 0.53, P =0.006) and quartile 4
(r = 0.53, P=0.008). No correlation was found in quartile 1.
In all the patients, the correlation between the
APACHE II score and MR-proADM was significant with
a p value < 0.0001 and r = 0.39, while the correlation be-
tween the APACHE II score and PCT was significant
with a p value = 0.003 and r = 0.30.
Moreover, the correlation between the APACHE II
score and the two biomarkers MR-proADM and PCT
was tested in the following groups of patients, divided
according to the final ED’s diagnosis: respiratory infec-
tions group, urinary infections group, sepsis and septic
shock group, unspecified fever group, and “other” group
(Table 2).
In the respiratory infections group a positive cor-
relation was found between the APACHE II and
MR-proADM (r = 0.66, P = 0.0002) and between
MR-proADM and PCT(r = 0.54, P = 0.0001). The urinary
infections group showed a positive correlation between
the APACHE II and MR-proADM (r = 0.50, P = 0.001)
and between MR-proADM and PCT(r = 0.61, P = 0.0007).
In the sepsis-septic shock group a positive correlation
was found between the APACHE II and MR-proADM
(r= 0.66, P = 0.02) and the APACHE II and PCT (r= 0.65,
P = 0.02). In the remaining groups, no statistically sig-
nificant correlations were identified.
Hospitalization prediction
We evaluated the ability of MR-proADM and PCT to
predict hospitalization in patients admitted to our emer-
gency departments complaining of fever. The patients
hospitalized after ED admittance were 99. MR-proADM
alone had an AUC of 0.694 (p = 0,0002), while PCT alone
Figure 1 Levels of MR-proADM and PCT at admission.
(a) MR-proADM in all patients versus healthy control individuals.
(b) PCT in all patients versus healthy control individuals. Lines
denote median values, boxes represent 25–75th percentiles and
whiskers indicate the range. The numbers of samples are indicated
in parentheses. proADM: mid-regional pro-adrenomedullin; PCT:
procalcitonin.
Figure 2 Correlation between MR-proADM and PCT. MR-
proADM levels increase in according to PCT values in all patients.
The dashed line represents the median in controls.
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had an AUC of 0.763 (p = 0,0001). The combined use of
PCT and MR-proADM instead showed an AUC of 0.79
(p = 0,0001). Results are summarized in Figure 4.
Discussion
In the present study we attempted to evaluate whether
MR-proADM and PCT could play a relevant role in de-
cision making for the disposition of the febrile patients
in the ED. We tried to understand the real diagnostic
and prognostic weight of the two biomarkers for the
emergency physician in taking care of a critical febrile
patient.
First we tested the diagnostic relevance of infection for
the two biomarkers, comparing the values detected in
patients with those of healthy control individuals.
According to literature [6-8], our data confirmed higher
values of both biomarkers in febrile patients compared
to healthy controls (Table 1b).
PCT added diagnostic value to the currently routine
variables (CRP, WBC count) for the identification of in-
fection in patients with fever. A negative value of PCT
should be of relevance in ruling out the presence of
infections, which is helpful when choosing the admitting
ward and/or antibiotic treatment [14].
Concerning the prognostic role of MR-proADM and
PCT, we evaluated the ability of MR-proADM and PCT
in predicting the subsequent hospitalization of patients
who arrived at the ED complaining of fever. Our data
demonstrated a better predictive value, even slightly, for
PCT than MR-proADM (AUC of 0.763 and a p =0, 0001
versus an AUC of 0.694 and a p =0, 0002, respectively).
The hospitalization’s predictive value rose if the
two biomarkers were used together (AUC of 0.79 and
p =0, 0001 – Figure 4).
Focusing on data emerging from this study, we can
highlight that MR-pro ADM and PCT levels are elevated
in critically ill febrile patients, and that they seem to
have a prognostic value similar to the APACHE II score,
providing an additional margin of safety. Thus, we evalu-
ated the potential correlation between the two molecules
and the APACHE II score, to determine the possible
additional value of PCT and MR-proADM in predicting
the outcome of the febrile patient attending the ED
[14-18]. The APACHE II score has been expressed in
predicted mortality percentage.
The Apache II score was grouped into quartiles
and compared with levels of MR-proADM and PCT.
MR-proADM and PCT levels were significantly step-
wise increased in accordance with the Apache II quar-
tiles with a p value< 0.0001 and= 0.0012 respectively
(Figure 3a, b), proving that a higher value of
MR-proADM and of PCT corresponds to a higher
APACHE II score.
A positive correlation between the APACHE II
score and both biomarkers was found in all patients,
considered in their globality, with a p <0.0001 for
MR-proADM and a p =0.003 for PCT.
Although a direct correlation between MR-proADM
and PCT and mortality cannot be shown, the correlation
between the two biomarkers and the APACHE II score
seems to assert their prognostic role in the febrile pa-
tient attending the ED, suggesting that MR-proADM
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Sepsis 20 Sepsis 18 1.82 (0.70-5.72) 2.49 (0.24-16.51) 21 (10.25-29.4)
Septic shock 2






COPD: chronic obstructive pulmonary disease; TB: tuberculosis.
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may predict mortality in a larger number of clinical con-
ditions, compared to PCT. Moreover, we found a step-
wise increase of MR-proADM levels with PCT values
(P< 0.0001 - Figure 2).
To date, PCT is described as a marker of bacterial in-
fection, but it has also been proposed and identified as a
mortality predictor in patients with community-acquired
pneumonia, in critically ill patients with sepsis, and in
those with ventilator associated pneumonia [19-23]. In
order to support this, several studies have demonstrated
the diagnostic role of PCT in detecting bacterial infec-
tion and sepsis [14,24-26], and further papers have
investigated its prognostic value [27-33]. In this perspec-
tive, our data suggest that the positive correlation
between PCT and the APACHE II score in febrile
patients who arrive in the ED correspond to the prog-
nostic value of the APACHE II score [34-37]. Moreover
our data show that higher levels of PCT are related to
more-severe infections and worse prognosis, as evi-
denced by the following division of the patients into 5
groups based on the clinical diagnosis made in the ED:
respiratory infections group, urinary infections group,
sepsis and septic shock group, unspecified fever group,
and “other” group (Table 2). In patients so grouped, a
positive correlation between the APACHE II score and
MR-proADM was found in the respiratory infections
group (r = 0.66, P = 0.0002), in the urinary infections
group (r = 0.50, P = 0.001) and in the sepsis and septic
shock group (r = 0.66, P = 0.02). For PCT, the positive
correlation with the APACHE II score was found only in
the sepsis and septic shock group (r = 0.65, P = 0.02).
We can also suggest that the use of these biomarkers
in the febrile patient could not only improve diagnostic
and prognostic accuracy, but could also promote a ra-
tional use of antibiotics, in terms of reduction of anti-
biotic overconsumption and adverse events as shown in
recent studies that point to the effectiveness of PCT in
safely reducing the number of unnecessary antibiotic
prescriptions [2,38-45].
Conclusions
The present study has highlighted how MR-proADM
and PCT may be helpful to the febrile patient’s care in
the emergency department. Our data support the
Figure 3 Correlation between APACHE II quartiles and MR-
proADM (fig. 3a) and PCT (fig. 3b). 3a) Apache II quartiles (Q1-4)
vs MR-proADM levels: Q1 0.54 (0.39-0.68), Q2 0.75 (0.53-1.50), Q3 1.61
(0.67-2.08), Q4 2.75 (1.18-5.30). 3b) Apache II quartiles (Q1-Q4) vs PCT
levels: Q1 0.27 (0.08-0.75), Q2 0.44 (0.11-1.98), Q3 1.40 (0.21- 3.69),
Q4 2.79 (0.75-19.74). Lines denote median values, boxes represent
25–75th percentiles and whiskers indicate the range.
Figure 4 Combined used of MR-proADM plus PCT in predicting
hospitalization. Area under the ROC curve (AUC) 0,79; standard
error 0,0426, 95 % Confidence interval 0,704 to 0,861; significance
level P (Area = 0.5) 0,0001.
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prognostic role of MR-proADM and PCT in that setting,
as demonstrated by the correlation with the APACHE II
score, particularly in respiratory tract infections, urinary
tract infection, and sepsis. Also of interest is the possibil-
ity that the combined use of the two biomarkers can
predict a subsequent hospitalization of febrile patients
accessing the ED.
The rational use of these two molecules could lead to
several advantages, such as faster diagnosis, more accur-
ate risk stratification, and optimization of treatment,
with consequent benefit to the patient.
Our study has some obvious limits, including a rela-
tively small patient sample and lack of follow-up. It
would be useful to conduct additional studies to further
validate the role of both MR-proADM and PCT in fe-
brile patients’ care in the emergency department.
Key messages
1. Fever is one of the most frequent signs seen in
emergency departments (ED) and in the critical care
setting in general. It is a priority because delayed
diagnosis of infection can lead to sepsis with high
morbidity and mortality.
2. Modern medicine requires optimizing resources and
time when evaluating patients with fever. To this
end, medical literature focuses on identifying
biomarkers as diagnostic and possibly prognostic
indicators. Among the biomarkers that can play a
role are PCT and MR-ProADM.
3. The positive correlation between these two
molecules and the APACHE II score demonstrate
their prognostic value, especially in selected groups
of patients, such as those with respiratory and
urinary tract infections and those with sepsis and
septic shock.
4. The combined use of PCT and MR-ProADM can
help predict the hospitalization of patients that
come to the ED complaining of fever.
5. The combined use of these two biomarkers can
improve the management of febrile patients in the
ED and in the critical care setting in general.
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